←
Raffaele Colombo1,673 posts
Raffaele Colombo avatar

Raffaele Colombo

@raffcolo

ADCs, targeted therapies, chemistry, biotech, pharma. Director @ Zymeworks

◷ Joined October 2022▧ 546 Photos and videos
Raffaele Colombo avatar
Raffaele Colombo@raffcolo·Nov 15

TROPION-Breast01: dual primary endpoints of PFS and OS. PFS was positive and OS was not statistically significant (HR 1.01), FDA approved it. HARMONi: also dual endpoints, PFS met, OS not met, FDA sent a CRL. 🤔🤔🤔

🟡 Whoa, Sunday CRL for ivonescimab! “The FDA indicated that PFS benefit in the absence of a statistically significant OS benefit does not support a positive benefit-risk profile in support of approval.”

Post attachment
Raffaele Colombo avatar
Raffaele Colombo@raffcolo·Nov 15

🟡 Whoa, Sunday CRL for ivonescimab! “The FDA indicated that PFS benefit in the absence of a statistically significant OS benefit does not support a positive benefit-risk profile in support of approval.”

Post attachment
Raffaele Colombo avatar
Raffaele Colombo@raffcolo·Nov 12

Also a reminder that QCS TROP2 NMR score is not going to work in all the settings. We already know that it doesn't discriminate patients with EGFRm NSQ NSCLC. Datapresented at #ELCC26 earlier this year from TROPION-Lung01 and -Lung05! PFS essentially superimposable (HR=0.95)

Post attachment

TROP2 NMR score paper out on @NatureMedicine Reminder: NMR+ = lower ratio of [membrane/(membrane + cytoplasm)] = more TROP2 in the cytoplasm than membrane Figure 👇 from #WCLC24 presentation was more informative with definitions, IMHO! nature.com/articles/s41591-0…

Post attachment
Raffaele Colombo avatar
Raffaele Colombo@raffcolo·Nov 3

Coincidentally, a Letter to the Editor was published on @JournalofNucMed a day before my post, with comment of ADC stability in the context of TROP2 immuno-PET: jnm.snmjournals.org/content/… Related article on [18F]AIF-RESCA-RT4: jnm.snmjournals.org/content/… Worth a read!

Post attachment

Great editorial by D. Rimm: academic.oup.com/jnci/advanc… One other caveat is the chemistry of ADCs. The meta-analysis combined SG (ADC half-life ~20h), Sac-TMT (~36h), and dato-DXd (4.8 days). Relevance of target expression must be considered alongside ADC half-life and stability!

Post attachment
Adam C Palmer avatar
⟳ Raffaele Colombo retweeted
Adam C Palmer@ac_palmer·Nov 2

With many new cancer medicines, reminder that the clinical effectiveness of drug combinations is highly predictable from the clinical effectiveness of single agents 100% sensitive prediction of phase 3 trial success across all advanced cancers, 1995-2020 nature.com/articles/s43018-0…

Raffaele Colombo avatar
Raffaele Colombo@raffcolo·Oct 30

Great editorial by D. Rimm: academic.oup.com/jnci/advanc… One other caveat is the chemistry of ADCs. The meta-analysis combined SG (ADC half-life ~20h), Sac-TMT (~36h), and dato-DXd (4.8 days). Relevance of target expression must be considered alongside ADC half-life and stability!

Post attachment